PD-1 Inhibitors Maintenance for cHL Post-autoHCT

This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL)

Trial Details

NCT ID
NCT06812858
Phase
PHASE2
Sponsor
St. Petersburg State Pavlov Medical University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Nivolumab, Pembrolizumab
Locations (sample)
  • Astana, Kazakhstan|51.1801,71.44598
  • Moscow, Russia|55.75204,37.61781
  • Moscow, Russia|55.75204,37.61781
  • Saint Petersburg, Russia|59.93863,30.31413

Key Eligibility Criteria

  • 18-70 years;
  • Diagnosis of r/r cHL with auto-HCT being performed as consolidation of 2 or later therapy lines;
  • High-risk cHL (Primary refractoriness after first-line therapy / Relapse after first line therapy within 12 months / PET/CT-positive status at the …
  • Complete or partial response by PET/CT after auto-HSCT

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →